OPKO Health, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
OPKO Health, Inc. (OPK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.71 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-26
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $0.71, a 7.79% decline from fiscal 2024.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $0.77, a 22.22% decline from fiscal 2023.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $0.99, a 23.26% decline from fiscal 2022.
- OPKO Health, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $1.29, a 50.76% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|
| 2025-12-31 | $0.71 10-K · filed 2026-02-26 | |
| 2024-12-31 | $0.77 10-K · filed 2026-02-26 | |
| 2023-12-31 | $0.99 10-K · filed 2026-02-26 | |
| 2022-12-31 | $1.29 10-K · filed 2025-03-03 | |
| 2021-12-31 | $2.62 10-K · filed 2024-03-01 | $2.68 10-K · filed 2022-03-01 |
| 2020-12-31 | $1.39 10-K · filed 2023-02-27 | |
| 2019-12-31 | $1.15 10-K · filed 2022-03-01 | |
| 2018-12-31 | $2.08 10-K · filed 2021-02-18 | |
| 2017-12-31 | $4.50 10-K · filed 2020-03-02 | |
| 2016-12-31 | $4.78 10-K · filed 2019-03-01 | |
| 2015-12-31 | $5.00 8-K · filed 2019-01-29 | |
| 2014-12-31 | $4.64 10-K · filed 2017-03-01 | |
| 2013-12-31 | $4.00 10-K · filed 2016-02-29 | |
| 2012-12-31 | $2.44 10-K · filed 2015-02-27 | |
| 2011-12-31 | $2.49 10-K · filed 2014-03-03 | |
| 2010-12-31 | $1.39 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |